ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
11 announcements with these filters
Tatva Chintan reported record quarterly revenue of ₹2,173 Mn for Q2 FY27, up 76% YoY, driven by strong SDA demand. EBITDA margins remained flat at 19% due to high solvent costs and freight spikes.
Tatva Chintan Pharma Chem Ltd reported revenue from operations of ₹217.3 Cr (+76.0% YoY) and net profit of ₹21.5 Cr (+117.2% YoY) for Q2 FY27.
The company has filed its quarterly shareholding pattern as per SEBI regulations. This routine disclosure provides details on the current shareholding structure.
Tatva Chintan Pharma Chem has scheduled a Board meeting for 19 October 2026 to consider Q1 FY27 financial results. The trading window will remain closed until 48 hours after results are published.
The company held its 30th Annual General Meeting on September 25, 2026. Shareholders considered and approved items including financial statements and director re-appointments.
CRISIL Ratings upgraded Tatva Chintan's long-term bank facilities to CRISIL A-/Stable and short-term facilities to CRISIL A2+. This upgrade reflects the company's improved credit profile.
Tatva Chintan Pharma Chem Limited submitted its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26. The report highlights its specialty chemicals operations and ESG metrics.
Tatva Chintan Pharma Chem Limited has submitted its Annual Report for the financial year 2025-26. The company's 30th Annual General Meeting is scheduled for September 25, 2026.
Tatva Chintan Pharma Chem Limited has scheduled its 30th Annual General Meeting for September 25, 2026. Key agenda items include dividend declaration and director re-appointments.
Tatva Chintan Pharma Chem Limited scheduled its 30th AGM for September 25, 2026. Key agenda items include dividend declaration and increasing borrowing limits to ₹1,000 Crore.
Tatva Chintan Pharma Chem announced the resignation of Mr. Ajay Rawat, Assistant Vice President – Research and Development, effective from November 13, 2026.